When asked about the company's plans for its cash flows, Bunch said PPG will continue its balanced approach towards its cash, which includes increasing its dividend and boosting its capital spending.
Cramer said PPG is a stock that is "not up enough" given its huge leverage to the return of the Chinese economy.
Executive Decision: Sandy Cutler
In his second "Executive Decision" segment, Cramer spoke with Sandy Cutler, chairman and CEO of
(ETN - Get Report)
, another Action Alerts PLUS holding. Eaton saw its shares pop 2.7% after its earnings release and it currently yields 2.75%.
Cutler confirmed the global economic outlook is sluggish, but added that execution matters for companies like Eaton, and his company has been executing very well. He noted that sales were up 24% and profits by 28% for the quarter, thanks to a $50 million restructuring effort, especially in Europe, to help streamline operations there.
Cutler said Eaton's electrical products, which now account for 60% of sales, have been led by innovations in LED lighting and also by moving the company's heavy-duty power equipment products downstream into medium-sized applications. He said that aerospace also continues to be strong for Eaton because the company has products in everything from business jets to large military helicopters.
In the construction market, Cutler said commercial construction is seeing activity in some segments and Eaton is seeing some growth return in the residential market as well.
Cramer once again gave his endorsement for owning Eaton, an industrial stock that's been bucking the weak global economy and still delivering for its shareholders.
In the Lightning Round, Cramer was bullish on
Cramer was bearish on
Executive Decision: Michael Bonney
In a third "Executive Decision" segment, Cramer sat down with Michael Bonney, CEO of
, a stock Cramer found out about from a caller inquiry during an earlier show.
Bonney said Cubist currently has three drugs in late-stage clinical testings, two of which are new antibiotics. He said his company is bullish on the prospects for all three drugs, including its urinary tract infection treatment, which could represent a $1 billion opportunity.
Regarding the Cubist's antibiotics, Bonney explained that nearly 1.7 million patients acquire infections while in hospitals every year and of those, 100,000 die from them. Given the widespread use of antibiotics in hospitals, Bonney said hospitals have also become hot-beds of drug-resistant antibiotics, which is why Cubist's new drugs are s desperately needed.
Bonney commented on the company's current legal battles regarding patent infringement. He said Cubist will be vigilant in protecting its patents and expects a ruling within the next 30 days. Of the five lawsuits the company has brought, he said only one needs to win in order to keep infringing products off the market.
Cramer said Cubist has a lot of good data points coming this year and investors need to do their homework and read up on the company's prospects.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer clarified his position on
(NFLX - Get Report)
, a company he said should be bought by either Apple or
Cramer said to be clear, he does
expect Netflix to actually be acquired by either company, but the exercise does show how investment bankers would approach such a merger.
He said that Apple has been trying to expand its TV offerings, and owning Netflix would allow it to bypass its major road block, the cable operators. Meanwhile, Microsoft already has integration with its Xbox, but could do a whole lot more if it owned the company outright. In either case, Cramer said that Netflix could recapitalize its balance sheet and negotiate even better deals for more content going forward.
Will it happen? Not likely. But is it interesting to speculate on the possibilities? Absolutely.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,